Mansoor Shahriari, Saeed Mehrzadi, Masood Naseripour, Iman Fatemi, Azam Hosseinzadeh, Mozhgan Rezaei Kanavi and Habib Ghaznavi* Pages 396 - 403 ( 8 )
Objective: The present study was designed to evaluate the effects of Atorvastatin (ATO) plus melatonin (MEL) on streptozocin-induced diabetic retinopathy (DR) in rats.Method: Diabetes was induced in Wistar rats with an intraperitoneal injection of streptozocin (50 mg/kg). Animals were randomly assigned to one of the following groups (8 rats/group): Control group, Diabetic group, Diabetic + MEL group (20 mg/kg/day), Diabetic + ATO group (10 mg/kg/day), Diabetic + MEL + ATO group (as above). Treatments were started one week after induction of diabetes and continued for 7 weeks. At the end of the experiment, angiography was performed and the rats were killed and retinas were harvested for pathological and molecular examinations. Results: Administration of MEL reduced the fluorescein leakage, MDA and ROS levels compared to diabetic group. Treatment with ATO only reduced ROS levels compared to diabetic group. In addition, administration of ATO plus MEL decreased these indices compared to the diabetic and ATO groups. Histologically, retinal vascular congestion was not observed in the combined ATO and MEL group as compared to the diabetic, ATO, and MEL groups. Conclusion: These data provide evidence for the therapeutic value of MEL in combination with ATO in clinical practice for prevention of DR.
Atorvastatin, melatonin, diabetic retinopathy, fluorescein angiography, reactive oxygen species.
Ophthalmic Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Research Center for Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Department of Pharmacology, Zahedan University of Medical Sciences, Zahedan